TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03736213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual-acoustic biofeedback
Description: In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultrasound biofeedback
Description: In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
Study: NCT00765011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF, radiotherapy and cetuximab
Description: 3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days

Intervention type: PROCEDURE
Group type: OTHER
Intervention: H&N surgery
Description: Rescue surgery
Study: NCT03961022

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyherbal supplement: ReWin(d) vs Placebo
Description: Supplementation during 4 weeks + 72 hours post acute exercice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Polyherbal supplement: ReWin(d) vs Placebo
Description: Supplementation during 4 weeks + 72 hours post acute exercice
Study: NCT00351598

Intervention type: RADIATION
Intervention: Definitive Radiotherapy
Description: 60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
Study: NCT03582280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Carbonate (ACC) - Amor
Description: Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
Study: NCT03036553

Intervention type: OTHER
Intervention: Diagnosis/Prognosis
Description: The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
Study: NCT03983252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical
Study: NCT01953939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prosthetic Limb Users
Description: There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
Study: NCT01922167

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Study: NCT00123955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25mg tablet daily for 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily for 9 months
Study: NCT02756247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study: NCT04231942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graduated Compression Stocking: continuous using
Description: Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graduated Compression Stocking: intermittent using
Description: Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
Study: NCT01565616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen with Bone Marrow Transplant
Description: The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV
Study: NCT02254369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02747758

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation (tDCS)
Description: transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (tDCS)
Description: transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
Study: NCT02350218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eglandin
Description: Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eglandin
Description: Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
Study: NCT03351946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP
Description: Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP
Description: Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
Study: NCT01999933

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin（DDP） weekly
Description: concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
Study: NCT02254369

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00375570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-609
Description: Topical treatment 5 times daily for 5 days
Study: NCT00362921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliadel wafers in combination with O6-benzylguanine
Study: NCT01999933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus cisplatin
Description: concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus cisplatin
Description: concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus cisplatin
Description: adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
Study: NCT00246363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Silymarin (milk thistle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02850978

Intervention type: DRUG
Intervention: Spiolto
Study: NCT02669589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate
Study: NCT00881894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours
Study: NCT00776360

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxytocin
Description: 80mIE/min as continuous infusion for 70 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: 80mIE/min as continuous infusion for 70 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxytocin
Description: 80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: 80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
Study: NCT03431597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: novel micronutrient
Description: The supplements will be supplied to participants on a daily basis. The novel micronutrient supplement will be provided in powder form with instructions to dissolve one sachet in 250ml of clean water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: existing micronutrient supplement, UNIMMAP
Description: UNIMMAP will be provided in tablet form and given one daily
Study: NCT04068922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Intervention
Description: Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
Study: NCT01478932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diaphragmatic breathing retraining
Description: In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Promotion
Description: n-person instructions will be given about what the intervention includes. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, health promotion topics will be discussed (lipid profile, healthy eating to improve lipid profile, importance of regular doctor visits, cancer screening, and so forth).
Study: NCT01832610

Intervention type: DEVICE
Intervention: HeartWare® VAS
Description: The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
Study: NCT03844308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isha Kriya Meditation
Description: Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Isha Kriya Meditation
Description: Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
Study: NCT04337684

Intervention type: DRUG
Intervention: Long Term Follow-Up
Description: Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up.
Study: NCT02365259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy
Description: Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
Study: NCT04691310

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio Tex Gold
Description: The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
Study: NCT03445312

Intervention type: BEHAVIORAL
Intervention: not processing urine cultures
Description: microbiology lab will not process culture unless called
Study: NCT00761345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
Study: NCT04691310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tex Gold
Description: The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
Study: NCT02801084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced environmental stimulation
Description: Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 \& 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart.
Study: NCT00761345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 100mg or 150mg daily of each 21 day cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose fractionated radiotherapy
Description: low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
Study: NCT01911455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acamprosate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01914250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic effect of topical tetracaine 2 %
Description: The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
Study: NCT03544450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial counselling
Description: Individuals with psychological distress receive psychosocial counselling and enhanced usual care. The psychosocial the counselling process consists of: (i) introduction, explanation and rapport building; (ii) assessment of and understanding of the problem (including looking for positive assets); (iii) goal setting (asking the client what outcomes are preferred); (iv) problem management (exploring and identifying solutions, brainstorming, working with existing coping strategies, using social and cultural resources, and additional techniques such as relaxation and psycho-education); (v) implementation (making a plan of action and transition); and, finally, (vi) termination of counselling (including closing and follow-up). Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
Study: NCT01742884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thealoz
Description: Instillation of 1 drop of Thealoz

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop of the vehicle will be instillated in the eye
Study: NCT02001129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Telephone System
Description: Participants receive automated reminder phone calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Telephone Call
Description: Participants receive reminder phone calls by study staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants receive a standard reminder letter in the mail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants receive a standard reminder letter in the mail.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receive a standard reminder letter in the mail.
Study: NCT02663310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
Study: NCT03940716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntERact
Description: This intervention integrates motivational interviewing, cognitive behavioral skills therapy, and care management into a single behavioral counseling intervention delivered by a therapist. The intervention is delivered either in the emergency department or remotely over the subsequent 5 weeks for a total of six therapy sessions (\~30 min each). A smartphone app is also loaded on the participant's phone and delivers additional behavioral intervention content, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact encouragement, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources.